Canadian application, no grantCanada
Skin photoageing and actinic damage treatment
CA 2499602 A1 · Owner: Novogen Research Pty Ltd · Inventors: Walker, Cath; Husband, Alan; Kelly, Graham Edmund
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use of equol, dehydroequol, and other isoflav-3-enes are described for the prevention and/or treatment of skin photoageing and actinic damage. Methods of treating these conditions are also described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 23, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 23, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 23, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledSeptember 23, 2003
GrantedNo grant recorded
Term endedSeptember 23, 2023
Patent numberCA 2499602 A1
Classification (IPC)A61K8/49 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.